Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07409324

Prophylactic Use of APRV Before Extubation in Morbidly Obese Patients After Cardiac Surgery.

Prophylactic Use of Airway Pressure Release Ventilation (APRV) Prior to Extubation in Morbidly Obese Patients Undergoing Elective Cardiac Surgery: Impact on Pulmonary Function, Oxygenation, and ICU Outcomes.

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
180 (estimated)
Sponsor
Ain Shams University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Morbidly obese patients undergoing open heart surgery are at increased risk of breathing problems after removal of the breathing tube due to reduced lung function and chest wall restriction following surgery. These complications may result in poor oxygenation, respiratory failure, and prolonged ICU stay. Airway Pressure Release Ventilation (APRV) is a mechanical ventilation mode that improves lung recruitment and oxygenation. This study aims to evaluate whether the prophylactic use of APRV after ICU admission, compared with conventional lung-protective mechanical ventilation, improves oxygenation, lung function, and ICU outcomes in morbidly obese patients undergoing elective cardiac surgery. Patients will be randomly assigned to receive either APRV or conventional ventilation during postoperative mechanical ventilation, followed by standard weaning and extubation. Outcomes include oxygenation index, lung ultrasound findings, need for reintubation, and ICU clinical outcomes.

Detailed description

Morbid obesity is increasingly prevalent among patients undergoing elective cardiac surgery and is associated with significant postoperative respiratory morbidity. Reduced functional residual capacity, impaired chest wall compliance, atelectasis, and diaphragmatic dysfunction are further exacerbated by median sternotomy, cardiopulmonary bypass, and postoperative pain. These factors increase the risk of hypoxemia, difficult weaning from mechanical ventilation, extubation failure, and prolonged intensive care unit (ICU) stay in this high-risk population. Conventional postoperative mechanical ventilation strategies in obese cardiac surgery patients typically rely on lung-protective volume-controlled ventilation with moderate to high positive end-expiratory pressure (PEEP). However, despite these strategies, postoperative atelectasis and impaired oxygenation remain common, particularly in morbidly obese patients. Airway Pressure Release Ventilation (APRV) is a pressure-controlled mode of ventilation characterized by prolonged periods of high continuous airway pressure with brief release phases, allowing spontaneous breathing throughout the ventilatory cycle. APRV has been shown to improve alveolar recruitment, ventilation-perfusion matching, and oxygenation while limiting alveolar collapse and reducing atelectrauma. Its physiological advantages suggest a potential role in preventing postoperative pulmonary complications when applied early in the ICU course. This randomized controlled study aims to evaluate the prophylactic application of APRV initiated upon ICU admission, compared with conventional lung-protective mechanical ventilation, in morbidly obese patients undergoing elective cardiac surgery. Mechanical ventilation will be applied according to group allocation until patients meet predefined criteria for extubation. Prior to extubation, both groups will be transitioned to standardized spontaneous breathing trials using continuous positive airway pressure (CPAP) or pressure support ventilation. The primary outcome of the study is oxygenation index measured at predefined time points, including on ICU admission, immediately prior to extubation, and after extubation. Secondary outcomes include lung ultrasound score, incidence of reintubation, duration of mechanical ventilation, ICU length of stay, postoperative pulmonary complications, and hemodynamic stability. By focusing on early postoperative ventilation strategy rather than rescue therapy, this study seeks to determine whether prophylactic APRV can improve respiratory physiology and clinical outcomes in morbidly obese patients following elective cardiac surgery.

Conditions

Interventions

TypeNameDescription
DEVICEAirway Pressure Release Ventilation (APRV)Patients will be ventilated using the Airway Pressure Release Ventilation (APRV) mode immediately upon ICU admission. This mode will be maintained throughout the postoperative period until the patient meets the clinical criteria for extubation. with the following standardized steps: Initial APRV Settings * P High: 20-25 cm H₂O * P Low: 0 cm H₂O * T High: 4.0-6.0 seconds * T Low: 0.5-0.8 seconds * FiO₂: Adjusted to maintain SpO₂ \>92% Note: P High may be titrated according to patient tolerance, Mean airway pressure (MAP), and plateau pressures. T Low is set to terminate expiratory flow at 50-75% to preserve lung recruitment. Weaning/Transition from APRV to Extubation Once oxygenation and ventilation criteria are met: * T High will be gradually increased (to ≥8 sec) and P High decreased (to 10-15 cm H₂O) * Then transition to CPAP/PS for 15-30 minutes Final decision for extubation will be based on successful spontaneous breathing trial (SBT) (RSBI \< 105) and clinical readiness
DEVICEConventional Lung-Protective Mechanical VentilationPatients will be ventilated using the SIMV Volume-Controlled mode with lung-protective strategies: * Tidal volume: 6-8 mL/kg of Ideal Body Weight (IBW) * PEEP: Set at 8-12 cm H₂O, individualized based on oxygenation status * Respiratory rate: Adjusted to maintain normocapnia, typically starting from 12-18 breaths per minute * FiO₂: Titrated to maintain SpO₂ \> 92% * Also transition to CPAP/PS for 15-30 minutes as a transition before extubation will be applied.

Timeline

Start date
2026-02-01
Primary completion
2026-10-01
Completion
2026-11-01
First posted
2026-02-13
Last updated
2026-02-13

Source: ClinicalTrials.gov record NCT07409324. Inclusion in this directory is not an endorsement.